Epigenomics AG Reports PRESEPT Clinical Study Progress
| March 17, 2009
(
)
|
Genetic Information Discrimination Act
| May 23, 2008
President Bush signed the Genetic Information Discrimination Act on May 21, 2008, ....(
)
|
Study Demonstrates Symptom Improvement in Adult Women with IBS-C
| May 21, 2008
RxTrials Institute Drug Pipeline AlertMay 21, 2008 | Vol. 6 No. 21 Study Demonstrates ....(
)
|
XenoPort and GlaxoSmithKline Report Positive Top-Line Results of Second Phase 3 Restless Legs Syndrome Trial for XP13512/GSK1838262
| January 15, 2008
XenoPort and GlaxoSmithKline Report Positive Top-Line Results of Second Phase 3 ....(
)
|
Reclast (r) receives US FDA approval as first and only once-yearly treatment for women with postmenopausal osteoporosis
| August 17, 2007
Reclast (r) (Zoledronic acid) receives US FDA approval for treatment of osteoporosis in postmenopausal women(
)
|
GlaxoSmithKline and XenoPort Announce Agreement on Late-Stage Compound for RLS and Neuropathic Pain
| February 8, 2007
London, UK, and Santa Clara, CA, February 8, 2007 GlaxoSmithKline (GSK) and XenoPort, ....(
)
|
XenoPort Announces Advancements in Clinical Development Programs
| January 9, 2007
SANTA CLARA, CA, January 8, 2007 XenoPort, Inc. (Nasdaq: XNPT) announced today that ....(
)
|
Xenoport - Restless Legs Syndrome
| June 21, 2006
XenoPort Announces Presentation of XP13512 (treatment of Restless Legs Syndrome) Data at the Associated Professional Sleep Societies Meeting.
(
)
|
XenoPort : XP13512 as a Treatment for Restless Legs Syndrome (Phase 3)
| March 17, 2006
..."possibility of providing a new treatment alternative for patients with RLS.”
RLS study XP060 to be done at Charlottesville Medical Research.(
)
|
Learn more about the individual studies we are
currently running or have recently participated in.
